TLR4 and endometrial cancer: Finally, to mimic the chronic inflammatory signals predisposing to endometrial cancer, we simultaneously treated benign organoids, which express LPS receptor, TLR-4 (Toll-like receptor 4) (Fig. 6B), with E. coli- derived LPS (O111:B4) and increasing LCC media concentrations for 24 h.